DPP4 and type 2 diabetes mellitus: With a low risk of hypoglycemia and no weight gain, nearly 0.7% reduction in HbA1c was reported when other DPP-4 inhibitors were given either alone or in combination with metformin for the treatment of T2DM patients [8–10].